Phil, Inc. Disrupting Traditional Hub Services Provider Market

Phil, Inc. (Phil) announced a partnership with Impel NeuroPharma, Inc. in support of Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) to provide technology-powered patient support and distribution services through Phil’s proprietary workflow to enhance the patient’s access to therapy. Trudhesa is indicated for the acute treatment of migraine with or without aura in adults. 

“Every step of our Trudhesa development program has been guided by the needs of people living with migraine,” said Adrian Adams, Chairman and Chief Executive Officer, Impel NeuroPharma. “That’s why we’re excited to partner with Phil on Trudhesa Direct™, a streamlined, customized, end-to-end process that will automatically enroll eligible, commercially-insured patients in a savings program to obtain and conveniently ship the medication straight to their home at no additional cost. This partnership will create a customized and seamless experience for patients who choose Trudhesa for rapid, sustained and consistent migraine relief.” 

Phil is a software therapy deployment platform, offering pharmaceutical manufacturers a modern alternative to traditional access, affordability and distribution options. Through its digital stakeholder experiences, patient access services, market access solutions and distribution models, pharma manufacturers are able to deliver affordable and timely therapy access to patients.

Earlier this year, Phil announced a $56 million Series D fundraise led by Warburg Pincus, a leading global growth investor. The investment is part of an arrangement for Warburg Pincus to invest up to $100 million and enables Phil to accelerate the development of innovative products while continuing to support the growth of its customers.

A number of innovative companies have entered the increasingly competitive traditional specialty pharmaceutical Hub services market. Phil provides an integrated suite of solutions to offer pharmaceutical access, affordability, and distribution to the market.

Takeaway: Phil offers an affordable, next-generation market access platform delivering unique outcomes for patients, prescribers, manufacturers and all other industry stakeholders